The earnings call presented several positive developments, including strong revenue growth from Tyvaso DPI and Afrezza, a secure financial position with non-dilutive funding from Blackstone, and advancements in key development programs. However, there were challenges, such as a decline in V-Go revenue and the need for significant investment in the pediatric launch of Afrezza. Despite these challenges, the overall sentiment is optimistic due to the strategic focus and strong financials.

Company Guidance

During the MannKind Corporation's Second Quarter 2025 Financial Results Conference Call, CEO Michael Castagna outlined several key metrics and strategic initiatives set to guide the company's growth in the coming quarters. The company reported Q2 revenues of $77 million, marking a 6% increase over the previous year, and year-to-date revenues of $155 million, a 12% rise from 2024. Afrezza, MannKind's rapid-acting inhaled insulin, contributed $18 million in revenue for Q2, showing a 13% growth year-over-year. The partnership with Blackstone was highlighted as a significant development, providing MannKind with access to $500 million in nondilutive capital to further its growth and innovation. Additionally, MannKind's balance sheet was strong with $201 million in cash. Castagna emphasized the potential of the company's pipeline, including the advancement of the inhaled clofazimine and Nintedanib DPI programs, with plans for the INFLO trial launch by the end of 2025. The TETON 2 readout, expected in September, was noted as a potential catalyst for future business plans. The company's strategic focus includes expanding its presence in the U.S. and Japan markets, leveraging a strong balance sheet, and continuing to drive growth in its core business areas.

Record Revenue from Tyvaso DPI Sales

Achieved record Tyvaso DPI sales, contributing $31 million in royalty revenue for Q2 2025, marking a 22% increase over the same quarter last year.

Afrezza Revenue Growth

Afrezza net revenues for the second quarter were $18 million, showing a 13% increase over the prior year, with notable growth in prescriptions.

Strong Financial Position and Non-Dilutive Financing

MannKind secured up to $500 million in non-dilutive funding from Blackstone, reinforcing a strong liquidity position with $201 million in cash at the end of Q2.

Advancements in Inhaled Clofazimine and Nintedanib DPI

Progress in inhaled clofazimine development with 90 patients enrolled, and Nintedanib DPI moving forward into Phase II with plans to launch the INFLO trial by year-end 2025.

Endocrine Business Unit Performance

The endocrine business unit had strong performance in Q2 with $18.3 million in revenue, marking a 13% growth over 2024.

MannKind (MNKD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MNKD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.03 / -	0.04	―	―	―
Aug 06, 2025	2025 (Q2)	0.05 / 0.00	-0.01	―	―
May 08, 2025	2025 (Q1)	0.04 / 0.04	0.04	0.00% (0.00)	―
Feb 26, 2025	2024 (Q4)	0.04 / 0.03	0	―
Nov 07, 2024	2024 (Q3)	0.03 / 0.04	0.01	300.00% (+0.03)	―
Aug 07, 2024	2024 (Q2)	<0.01 / -0.01	-0.02	50.00% (+0.01)
May 08, 2024	2024 (Q1)	0.03 / 0.04	-0.04	200.00% (+0.08)
Feb 27, 2024	2023 (Q4)	<0.01 / 0.00	-0.07	―
Nov 07, 2023	2023 (Q3)	-0.02 / 0.01	-0.06	116.67% (+0.07)	―
Aug 07, 2023	2023 (Q2)	-0.04 / -0.02	-0.11	81.82% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MNKD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$3.99	$3.46	-13.28%
May 08, 2025	$4.85	$4.63	-4.54%
Feb 26, 2025	$5.47	$5.23	-4.39%
Nov 07, 2024	$7.39	$7.34	-0.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mannkind Corp. (MNKD) report earnings?

Mannkind Corp. (MNKD) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Mannkind Corp. (MNKD) earnings time?

Mannkind Corp. (MNKD) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MNKD EPS forecast?

MNKD EPS forecast for the fiscal quarter 2025 (Q3) is 0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing